Figure 3 | Scientific Reports

Figure 3

From: Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming

Figure 3

Topotecan causes a decrease in the levels of SUMOylated proteins in GBM, neuroblastoma and E18 primary cortical neurons. U251 (A), LN229 (B), and Mz18 (C) at concentrations of 1 μM and 10 μM, and neuroblastoma line SH-SY5Y (D) and rat E18 primary cortical neurons (E) at 10 μM. Representative immunoblots are shown. High molecular weight (>100 kDa) SUMO-1 and SUMO-2/3 conjugates were cropped in each lane and the total intensities were measured. Densitometries were normalized to corresponding actin levels and expressed as a fold difference relative to the control (DMSO). Data are means (±SD) from n = 3 independent experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 vs. DMSO.

Back to article page